Business News • PR NewsWire • Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY™ (romosozumab)

Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY™ (romosozumab)

Amgen And UCB Report New Data At ENDO 2017 Examining The Option Of A Second Course Of Treatment With EVENITY™ (romosozumab)

THOUSAND OAKS, Calif. and BRUSSELS, April 1, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and UCB (Euronext Brussels: UCB) today announced results from the fourth year of a Phase 2 study showing the efficacy and safety of a second course of treatment with EVENITY™* (romosozumab), an...

View More : http://www.prnewswire.com/news-releases/amgen-and-ucb-report-new-data-at-endo-2017-examining-the-option-of-a-second-cour...

Releted News by prnewswire

Shanghai Hosts Second Edition of Asia Art and Finance Forum

New, Strikingly Different Refrigerator Finishes From Jenn-Air

Arctech Solar Ranked No. 5 Global Tracker Supplier in IHS' 2016 Markit Report